TacticScaleWhat Quest Diagnostics Does & How It Makes Money (DGX)
Updated October 2026 · reflects Quest Diagnostics's latest reported financials
U.S. provider of diagnostic lab testing and health information services. It earns fees for each diagnostic test and service it performs, paid by health plans, government programs, physicians, hospitals, employers and patients.
How Quest Diagnostics makes money
It earns fees for each diagnostic test and service it performs, paid by health plans, government programs, physicians, hospitals, employers and patients. Extra revenue comes from insurance risk assessment, hospital lab management and healthcare IT and data services.
What Quest Diagnostics does
Quest Diagnostics, founded in 1967 and headquartered in Secaucus, New Jersey, is a U.S. diagnostic testing company. It collects specimens through patient service centers, phlebotomists in physician offices, mobile phlebotomists and nurses, then processes them in its laboratory network. Its tests cover routine clinical testing, anatomic pathology and specialty areas such as cardiometabolic and endocrine, cancer, infectious and autoimmune disease, neurology including Alzheimer's disease, toxicology and prenatal genetics. Beyond the lab, Quest operates several brands: AmeriPath and Dermpath Diagnostics for pathology, ExamOne for life insurance underwriting support, and Quanum for healthcare IT and digital connectivity. It also runs hospital labs as a contracted service and provides workplace drug testing, employer population health programs, extended care services and health data solutions. Its customers include physicians, hospitals, health plans, government agencies, employers, pharmaceutical companies and consumers.
Products & services
- Quest Diagnostics clinical testing
- AmeriPath anatomic pathology
- Dermpath Diagnostics
- ExamOne life insurance risk assessment
- Quanum healthcare IT
- Workplace drug testing
What is Quest Diagnostics worth?
On an owner-earnings DCF, Quest Diagnostics's most-likely value is about $247 versus a recent price near $231 (7% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$136) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Labcorp (LH) · QuidelOrtho (QDEL) · Dian Diagnostics (300244.SZ) · IQVIA (IQV) · IDEXX Laboratories (IDXX)